Literature DB >> 11062097

[Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm].

D Fuster1, R Herranz, J Alcover, J J Mateos, F Martín, S Vidal-Sicart, F Pons.   

Abstract

This study has aimed to evaluate the usefulness of repeated treatment with 89Sr in patients with prostate neoplasm and metastatic bone pain. Seventeen patients with partial or complete response after the first dose were retreated with two or more doses (total of 39 doses). The Karnofsky functional status, pain and degree of analgesia were assessed. After the first dose the response was good in 68% of the patients and partial in 32%. After the second dose, the response was good in 62% of the patients, partial in 15% and there was no response in 23% of the cases. The pre-treatment Karnofsky functional status and duration of the effect of 89Sr was lower after the second dose (p = 0.03, p = 0.02), but there were no statistically significant differences in the type of response. In conclusion, re-treatment with 89Sr can be administered safely and with a similar response to that achieved after the first dose.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062097     DOI: 10.1016/s0212-6982(00)71874-x

Source DB:  PubMed          Journal:  Rev Esp Med Nucl        ISSN: 0212-6982


  2 in total

Review 1.  Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals.

Authors:  Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2018-01-12

2.  EANM procedure guideline for treatment of refractory metastatic bone pain.

Authors:  Lisa Bodei; Marnix Lam; Carlo Chiesa; Glenn Flux; Boudewijn Brans; Arturo Chiti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.